Logo - springer
Slogan - springer

| Drugs in R&D

Drugs in R&D

Drugs in R&D

Editor: Anton van Rensburg

ISSN: 1174-5886 (print version)
ISSN: 1179-6901 (electronic version)

Journal no. 40268

Drugs in R&D publishes original research and reviews from all phases of drug development and on clinical use of drugs following approval.

Articles published in Drugs in R&D may be accompanied by lay-level summaries, to assist patients, caregivers  and others in understanding important medical advances.

The journal was re-launched in 2010 as the first Open Access journal from Adis, making all content from 2010 onwards freely available online. Pre-2010 content is not available as Open Access.

Manuscripts submitted to the journal for publication will be subject to a $3,000 article processing charge (APC) upon acceptance. Adis Open Access enables you to make your journal article freely available to anyone, in exchange for payment of APC. This option allows you, the author, to retain the copyright of the article according to the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC) License, which does not permit commercial re-use of the article. 

The journal will consider fee discounts for developing countries and this is decided on a case by case basis.

Related subjects » Adis

Abstracted/Indexed in 

Medline, PubMedCentral, SCOPUS, EMBASE, Chemical Abstracts Service (CAS), Google Scholar, Academic OneFile, CSA Environmental Sciences, EBSCO Academic Search, EBSCO Advanced Placement Source, EBSCO Biomedical Reference Collection, EBSCO Discovery Service, EBSCO Pharmacy Collection: India, EBSCO STM Source, Emerging Sources Citation Index, Expanded Academic, Health Reference Center Academic, Journals@OVID, OCLC, SCImago, Summon by ProQuest

For authors and editors

  • Aims and Scope

    Aims and Scope

    Close

    Drugs in R&D is an international, peer reviewed, open access, online only journal, and provides timely information from all phases of drug research and development that will inform clinical practice. Healthcare decision makers are thus provided with knowledge about the developing place of a drug in therapy.

    The Journal includes:

    • Clinical research on new and established drugs;
    • Preclinical research of direct relevance to clinical drug development;
    • Short communications and case study reports that meet the above criteria will also be considered;
    • Reviews may also be considered.

    Articles published in Drugs in R&D may be accompanied by lay-level summaries, to assist patients, caregivers and others in understanding important medical advances.

    The journal will consider fee discounts for developing countries and this is decided on a case by case basis.

    All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.

  • Submit Online
  • Instructions for Authors

    Instructions for Authors

    Close

  • Important Information for Authors

    Important Information for Authors

    Close

  • Disclosure of potential conflicts of int...
  • Copyright Information

    Copyright Information

    Close

    Copyright and Licence Agreement

    Open Access Drugs in R&D is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, go to: http://creativecommons. org/licenses/by-nc/4.0

    Journal ownership: Springer International Publishing Switzerland

    Copyright of articles: © The Author(s)

Alerts for this journal

 

Get the table of contents of every new issue published in Drugs in R&D.


Additional information